Key result
Planned network meta-analysis evaluates loop diuretics for all-cause mortality in chronic heart failure.
Why the study?
While furosemide is the most used loop diuretic in chronic heart failure, other loop diuretics may exhibit theoretical advantages.
Do different types of loop diuretics improve all-cause mortality compared to other loop diuretics, placebo, or standard of care in patients with chronic heart failure?
Systematic Review
Do different types of loop diuretics improve all-cause mortality compared to other loop diuretics, placebo, or standard of care in patients with chronic heart failure?
Answers are grounded in this paper and cite their sources.
This protocol outlines a planned systematic review and network meta-analysis to compare the efficacy and safety of all types of loop diuretics in patients with chronic heart failure.
BACKGROUND: Patients with chronic heart failure (CHF) experience congestion-related symptoms such as dyspnoea and oedema, both of which are associated with poor outcomes. Loop diuretics are the cornerstone to treat congestion and to maintain euvolemia. While furosemide is the most used loop diuretic, other loop diuretics may exhibit theoretical advantages. We aim to compare all types of loop diuretics for patients with CHF. METHODS: This protocol for a systematic review is conducted with guidance from the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols. We will include randomised clinical trials (RCTs) of loop diuretics with other loop diuretics, placebo, or standard of care in CHF patients. The search will be conducted across the major medical databases (including Medline, Embase, and Cochrane Central Register of Controlled Trials). The searches will begin in February 2025. The primary outcome will be all-cause mortality. Secondary outcomes will be all-cause hospitalization, serious adverse events (SAEs), and changes in body weight (kg). Data will be analysed by traditional meta-analyses, Trial Sequential Analyses (TSA), and network meta analysis. The risk of bias will be assessed using the Cochrane Risk of Bias tool-version 2. The certainty of the evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) and Confidence in Network Meta-Analysis (CINEMA) approach.
No takes yet. Share an insight, caveat, or question.
Taleghani et al. (2025) conducted a systematic review in chronic heart failure. loop diuretics vs. other loop diuretics, placebo, or standard of care was evaluated on all-cause mortality. This protocol outlines a planned systematic review and network meta-analysis to evaluate the effect of all types of loop diuretics on all-cause mortality in patients with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: